MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
IDEXX Laboratories Interest Expense 2011-2026 | IDXX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense IDEXX Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 29.8 M | 33.1 M | 31.1 M | 34.7 M | 37.2 M | 32 M | 29.2 M | 15.4 M | 5.39 M | 3.85 M | 3.55 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.2 M | 3.55 M | 23.2 M |
Quarterly Interest Expense IDEXX Laboratories
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 7.91 M | - | 8.65 M | 10.5 M | 13.1 M | - | 11 M | 8.32 M | 7 M | - | 7.13 M | 7.61 M | 7.58 M | - | 8.11 M | 9.5 M | 7.69 M | - | 7.09 M | 8.19 M | 8.39 M | - | 8.45 M | 8.46 M | 9.27 M | - | 9.76 M | 9.16 M | 8.59 M | - | 7.79 M | 8.2 M | 8.3 M | - | 7.75 M | 7.26 M | 6.3 M | - | 4.29 M | 2.96 M | 2.77 M | - | 1.46 M | 1.18 M | 835 K | - | 873 K | 926 K | 1.19 M | - | 928 K | 782 K | 728 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.1 M | 728 K | 6.4 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 5.31 | 4.89 % | $ 156 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 20.49 | -2.36 % | $ 215 M |  China |
 |
Castle Biosciences
CSTL
|
1 K | $ 38.74 | -0.41 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
-56 M | $ 228.43 | -0.21 % | $ 167 B | USA |
 |
DexCom
DXCM
|
20.3 M | $ 66.86 | 0.74 % | $ 25.8 B | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.56 | 1.96 % | $ 1.98 M | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 11.42 | 0.35 % | $ 324 M |  Israel |
 |
IQVIA Holdings
IQV
|
670 M | $ 225.43 | 0.01 % | $ 40.9 B | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 101.79 | 0.23 % | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 25.95 | -1.24 % | $ 785 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
CareDx, Inc
CDNA
|
1.34 M | $ 19.2 | 1.91 % | $ 1.03 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 100.08 | 0.34 % | $ 3.95 B | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 3.09 | -0.96 % | $ 98.6 K | USA |
 |
Myriad Genetics
MYGN
|
1.1 M | $ 6.22 | 1.14 % | $ 564 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 4.26 | -5.96 % | $ 2.29 M | USA |
 |
NeoGenomics
NEO
|
-379 K | $ 11.76 | - | $ 1.49 B | USA |
 |
Guardant Health
GH
|
-42.6 M | $ 101.08 | -1.04 % | $ 12.4 B | USA |
 |
National Research Corporation
NRC
|
862 K | $ 18.42 | -1.89 % | $ 452 M | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.26 | 0.4 % | $ 874 M | USA |
 |
Precipio
PRPO
|
-1 K | $ 24.92 | 8.46 % | $ 32.3 M | USA |
 |
Personalis
PSNL
|
24 K | $ 7.76 | -2.52 % | $ 460 M | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Illumina
ILMN
|
-292 M | $ 132.27 | 0.85 % | $ 21 B | USA |
 |
Charles River Laboratories International
CRL
|
-16.5 M | $ 200.24 | 0.38 % | $ 10.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
30 M | $ 172.79 | -0.43 % | $ 19.2 B | USA |
|
Biodesix
BDSX
|
8.26 M | $ 6.84 | 0.51 % | $ 887 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 27.14 | 0.22 % | $ 20 B |  Niderland |
 |
Laboratory Corporation of America Holdings
LH
|
208 M | $ 250.12 | -0.3 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 186.86 | 2.55 % | $ 15.4 B |  Irlanda |
 |
Lantheus Holdings
LNTH
|
37.2 M | $ 66.89 | 0.51 % | $ 4.63 B | USA |
 |
Mettler-Toledo International
MTD
|
74.6 M | $ 1 395.51 | 0.09 % | $ 29.6 B |  Schweiz |
 |
Agilent Technologies
A
|
81 M | $ 136.02 | -0.04 % | $ 41.4 B | USA |